breast%20cancer
BREAST CANCER
Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the breast. The lump or mass is usually painless, hard & irregular but it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple discharge, nipple retraction and presence of breast skin changes (eg peau d' orange, nipple excoriation, scaling, inflammation, skin tethering, ulceration, abscess).
Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Palliative treatment of hormone-dependent advanced prostate cancer. High-risk localized & locally advanced...

Halaven
eribulin mesylate

Indication: Locally advanced or metastatic breast cancer who have progressed after at least 2 chemotherapeutic regimen for...

Indication: In combination w/ letrozole for the treatment of postmenopausal women w/ estrogen receptor (ER) +ve, human epi...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Tab: Multiple myeloma, advanced ovarian adenocarcinoma, breast carcinoma, polycythaemia rubra vera. Inj: Local...

Indication: Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clin...

Indication: Primary treatment of ovarian cancer in combination w/ platinum agent. Metastatic ovarian or breast cancer, aft...

Indication: Adjuvant treatment of post-menopausal women w/ estrogen receptor +ve early breast cancer who have received 2-3...

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 16 Dec 2019
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Elaine Soliven, 17 Dec 2019
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
21 Jan 2020
Peripheral T cell (PTCL) and natural killer/T cell (NKTCL) non-Hodgkin lymphoma have poor prognoses in elderly adults, though intensive chemotherapy may yield benefit for some, a recent study has found.